# NEORNAT

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neornat

- Industry: Pharmaceuticals
- Headquarters: Seoul, South Korea
- Website: www.neornat.com
- Total disclosed funding: $2.5M
- Latest round: Series A (Mar 29, 2022)
- Investors on record: 5

## About

Founded in 2020 and based in Seoul, South Korea, NEORNAT specializes in the development of macrophage immuno-oncology drugs and RNA regulator-targeted anticancer drugs. In March 2022, NEORNAT raised KRW 3 billion in Series A funding from Shinhan Capital and DB Financial Investment, DTR Partners, Lab Genomics, and Lead Compass Investment. As of April 2022, the company is led by its CEO Nam Seok-Woo.

The company develops liver cancer-specific RNAi treatment, RNA control-based liver cancer-targeting anticancer drug development proceeds, and multi-marker panel for whole-cycle liver disease diagnosis based on big data. The products in the company's pipeline include RT-LET7, RT-SF3B?, RT-SMAR, and RD-LCMD.

The company plans to use the Series A funding for the possession of new RNA-based drug development technology.

## Funding rounds

- Series A, Mar 29, 2022, $2.5M — DB Financial Investment, Shinhan Capital, LabGenomics. Co., Ltd., GeneN Investment Partners, DTR Partners

## Investors

- DB Financial Investment — Series A
- Shinhan Capital (https://capitalatlas.ai/funds/shinhan-capital) — Series A
- LabGenomics. Co., Ltd. — Series A
- GeneN Investment Partners (https://capitalatlas.ai/funds/genen-investment-partners) — Series A
- DTR Partners (https://capitalatlas.ai/funds/dtr-partners) — Series A